EN DE
Watch Viatris Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Viatris Inc (VTRS) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of Viatris Inc stock $20.56, price $18.97, upside +8.4%, quality 49 out of 100. Rating: fairly valued. Calculated from audited financials with 8 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

VI Viatris Inc logo Some data Nov 4, 2026

Viatris Inc

VTRS · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Generates free cash flow
2.5% dividend yield · Cash covered
Ranks above peers (8/13)
Positive coverage
Fair value $20.56 · Fairly valued (+8.4%)
Quality 49/100
Moderate debt
Insiders sold $809,729 (6M)
Some data
Profit last quarter 71% below a year ago.
Weak Growth (revenue 3y −4.2 %/yr in USD)
Loss-making · -2.8% net margin (TTM)
Narrow moat 24/100 · thin data

Risks from the AI analysis

🚩Rivals like Teva and Sandoz erode generic prices🚩FDA actions on India plants disrupt supply🚩Generic erosion hits Pacira pain drugs
Watch Viatris Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$19.22 $6.83 Fair Value $20.56 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range $6.83 – $19.22 · fair‑value band $8.75 – $36.15 · the $18.97 price screens below the $20.56 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 4, 2026.

Follow Viatris in your weekly email

Every Wednesday you see whether Viatris is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.

Show moreShow less

It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.

It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.

In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions.

It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands.

The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin.

Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Stock analysis

Viatris Inc (VTRS) currently trades at $18.97, while our model-based Fair Value estimate is $20.56, so the stock looks roughly fairly valued today (gap 7.7%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $20.56 per share, and 5 of the 8 models we run sit above the $18.97 price.

Bear case: the Multiples group reads lowest at $10.30, and 3 of the 8 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $8.75 (bear) to $36.15 (bull), the price of $18.97 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Viatris Inc reported revenue of $14.3B in FY2025 versus $17.9B in FY2021, a compound −5.4%/yr. Reported net income was −$3.5B in FY2025.

Key figures

Market cap $22.1B Large · P/S ratio 1.45 · EPS (TTM) $−0.3600 · Dividend yield 2.5% · Net margin −2.8% · Return on equity −2.8% · Return on assets (EBIT) −0.5% · Operating margin 12.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (low confidence).

What moves the price

The share trades about 1% below its 52-week high and 94% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 8%, VTRS screens cheaper than that median.

Fair Value models

Bear $8.75 Fair Value $20.56 Bull $36.15
Price $18.97 · Upside +8.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $15.81 $35.23 $68.39 73
Growth DCF $15.77 $34.02 $64.67 72
5Y EBITDA Exit n/a $1.53 $3.72 69
All 8 models by family
DCF Models
FCF DCF $15.81 $35.23 $68.39 73
5Y Revenue Exit $8.75 $20.56 $36.15 67
5Y EBITDA Exit n/a $1.53 $3.72 69
10Y Revenue Exit $10.41 $22.33 $39.71 61
10Y EBITDA Exit $4.71 $8.49 $12.97 65
Multiples
EV/Revenue $3.72 $10.30 $16.88 50
Growth DCF
Growth DCF $15.77 $34.02 $64.67 72
Rev-Margin DCF $8.75 $20.47 $35.31 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 18
Are margins and returns getting better?
Cashflow 68
Do the profits arrive as real cash?
Financial strength 29
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 67
How calm the share price moves, does not count
Price momentum 74
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 99
Distance to the 52-week high, does not count
New shares 91
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $809,729 and none bought.

  • SalePaul CampbellOfficer2× since Mar 23, 2026: 71,426 shares, avg. $15.31$1.1MJun 25, 2026

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 5, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 37/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−3.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
Start year 2020 (pandemic). Over 10 years: +4.3% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.8% (2020) → −18.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+2.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +3.1% a year for the price and −0.3% for the forecasts.
Forecast 2026 (sales)+3.4%
Forecast 2027 (sales)+1.7%
Projected 2028 (sales)+1.7%
Projected 2029 (sales)+1.8%
Projected 2030 (sales)+1.8%

Watch VTRS, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 11, 2026
AI conclusion: Viatris draws on its scale in generic pharmaceuticals as main strength but remains constrained by sustained net losses, negative return on equity and typical industry price erosion.
Main risk: Other large generic manufacturers such as Teva, Sandoz and Sun Pharma could intensify price competition through tenders and multi-source entries, squeezing margins on Viatris's standard oral generics and complex formulations.
Bull case: Viatris could leverage its scale and regulatory expertise to win more complex generic approvals and extend lifecycles of the Pacira assets through new formulations or indications.
Bear case: Persistent price erosion from multiple rivals combined with repeated manufacturing disruptions could shrink the generics base faster than new assets offset, leaving the company with a narrower portfolio of lower-margin products.
Viatris is acquiring Pacira to bring in two marketed non-opioid pain treatments along with their commercial team. The deal supports its push into higher-value branded medicines while it still relies heavily on generics. Will the new assets drive meaningful growth in innovative therapies or mainly add integration costs without shifting the business mix fast enough?
Join the discussion →

Compare Viatris Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 552 stocks

Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside +8.4% · Above median
Profitability
Return on assets −9.5% · Bottom 25%
Net margin (12 months) −2.8% · Bottom 25%
Operating margin (12 months) 12.6% · Above median
Growth and dividend
Revenue growth (quarter YoY) 4.9% · Above median
Dividend yield (12 months) 2.5% · Above median
Balance sheet
Debt / equity 0.85× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.50× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 1.50× · Cheaper than median
Price / free cash flow 11.4× · Cheapest 25%
EV/EBITDA 7.7× · Cheaper than median
PEG 1.05× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)45 · sector 16
FUTURE (revenue growth)25 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)58 · sector 96
DIVIDEND (yield)51 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.11 $110.26 +34% vs VTRS
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,829 ₹1,947 +6% vs VTRS
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.19 ¥53.31 +6% vs VTRS
Haleon plc HLN $9.15 $8.59 −6% vs VTRS
Merck KGaA MRK €150.35 €109.18 −27% vs VTRS
Galderma Group GALD CHF 195.15 CHF 109.26 −44% vs VTRS
Takeda Pharmaceutical Company TAK $21.19 $11.34 −46% vs VTRS
Teva Pharmaceutical Industries Limited TEVA $41.78 $20.75 −50% vs VTRS
Sandoz Group SDZ CHF 83.62 CHF 39.70 −53% vs VTRS
Divi's Laboratories Limited DIVISLAB ₹10,141 ₹1,567 −85% vs VTRS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Viatris Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Viatris Inc Fair Value". https://www.fairvalue-calculator.com/stock/VTRS

Frequently asked questions

Is Viatris Inc (VTRS) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $20.56 versus a price of $18.97, about +8% upside (fairly valued).
What is the fair value of VTRS?
Our model-based fair value for Viatris Inc is $20.56 (as of Nov 4, 2026), built from audited fundamentals. The current price: $18.97.
What is the quality score of VTRS?
Viatris Inc has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Viatris Inc (VTRS)?
Our model-based price target is the fair value of $20.56 (as of Nov 4, 2026) from 8 valuation models. Cautious scenario $8.75, optimistic scenario $36.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Viatris Inc stock forecast for 2026?
Our models put fair value at $20.56, about +8% upside versus a price of $18.97 (fairly valued). Cautious scenario $8.75, optimistic scenario $36.15. The calculation is refreshed regularly with new filings.
What is the revenue of Viatris Inc (VTRS)?
Viatris Inc reported trailing-twelve-month revenue of about $14.7B (latest available figure, as of Nov 4, 2026).
Does Viatris Inc pay a dividend?
Viatris Inc currently shows a dividend yield of 2.53% relative to its recent price (as of Nov 4, 2026).
What growth is priced into Viatris Inc (VTRS)?
For today's price to be fair in a discounted-cash-flow model, Viatris Inc would have to grow free cash flow by +5.6 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.7 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of VTRS use?
Our models discount Viatris Inc at 8.9 %: a base by market capitalisation (large), damped by beta 0.86, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Viatris Inc that is +5.6 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Viatris Inc (VTRS) delivered so far?
Over the past 5 years revenue at Viatris Inc grew +3.7 % a year. The price currently implies +5.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Viatris Inc (VTRS) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Viatris Inc (+5.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Viatris Inc (VTRS)?
The free-cash-flow yield on the price is 8.78 %: that much free cash flow Viatris Inc produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Viatris Inc (VTRS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Viatris Inc it is $20.56 per share (as of Nov 4, 2026), against a price of $18.97. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Viatris Inc stock overvalued or undervalued in 2026?
As of Nov 4, 2026, VTRS trades below its calculated fair value: price $18.97, fair value $20.56, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VTRS?
No. The price is what the market pays today ($18.97); the fair value is what the company's own numbers justify ($20.56). For Viatris Inc the two are $1.59 per share apart. That gap is exactly why we show both numbers side by side.
How much is Viatris Inc worth?
The market values Viatris Inc at about $22.1B (market capitalisation, as of Nov 4, 2026). Per share that is $18.97; our models calculate a fair value of $20.56 per share.
What do the bullish and bearish scenarios say about VTRS?
Our models span a range for Viatris Inc: cautious scenario $8.75, base $20.56, optimistic $36.15 per share (as of Nov 4, 2026, price $18.97). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of VTRS?
The PEG ratio of Viatris Inc is 1.05 (P/E divided by earnings growth, as of Nov 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Viatris Inc (VTRS)?
Balance-sheet figures for Viatris Inc (as of Nov 4, 2026): return on equity −2.8%, debt of 0.85 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is VTRS from its 52-week high?
Viatris Inc trades at $18.97, about 1% below its 52-week high of $19.22 and 94% above the low of $9.76 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $20.56 is for.
Which stocks are comparable to Viatris Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Viatris Inc stock attractive at the current price?
The data as of Nov 4, 2026: price $18.97, calculated fair value $20.56 (+8%), Quality Score 49/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VTRS calculated?
We run Viatris Inc through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $20.56, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Viatris Inc currently trades 8% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Viatris Inc (VTRS)?
The closing price on Nov 5, 2026 was $18.97. Our model-based fair value is $20.56, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Viatris Inc right now?
The model range is unusually wide ($8.75 to $36.15). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.

Key figures of Viatris Inc

How large is the market capitalisation of Viatris Inc (VTRS)?
The market capitalisation of Viatris Inc is $22.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Viatris Inc (VTRS)?
The price-to-sales ratio of Viatris Inc is 1.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Viatris Inc (VTRS)?
Earnings per share at Viatris Inc are $−0.3600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Viatris Inc (VTRS)?
The dividend yield of Viatris Inc is 2.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Viatris Inc (VTRS)?
The net margin of Viatris Inc is −2.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Viatris Inc (VTRS)?
The return on equity (ROE) of Viatris Inc is −2.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Viatris Inc (VTRS)?
On an EBIT basis the return on assets of Viatris Inc is −0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Viatris Inc (VTRS)?
The operating margin of Viatris Inc is 12.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Viatris Inc (VTRS)?
Revenue at Viatris Inc is growing +4.9% versus a year earlier (3y avg −4.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Viatris Inc (VTRS)?
Earnings per share at Viatris Inc are growing −70.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Viatris Inc (VTRS) carry?
The net debt of Viatris Inc is $13.4B (fiscal year 2025, ≈ 6.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Viatris Inc in the live analysis

One click puts Viatris Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.